en · de · es · pt
semax-notes.peptides1004.com › Blog › Background And Development History — Worked Examples

Background And Development History — Worked Examples

By Editorial Desk · published 2026-04-29 · last reviewed 2026-06-18 · Blog

ACTH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.

Background and Development History

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

Mechanism and Research

Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.

Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideAnalogue of the ACTH(4-10) fragment
Amino acid sequenceMet-Glu-His-Phe-Pro-Gly-ProSingle-letter form MEHFPGP
Molecular formulaC37H51N9O10SFree peptide, nominal mass near 814 Da
First registration1994, RussiaNasal formulation for neurological indications
Typical purity grade95% or higher by HPLCResearch material; higher grades used as reference standards

研发背景与监管地位

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax 是人工设计的七肽,序列为 Met-Glu-His-Phe-Pro-Gly-Pro,骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性,同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

Related pages on this site

Handling, Storage, and Analytical Methods

Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.

Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.

Semax Peptide Structure and Origin

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

Analytical Methods and Stability Profile

Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.

Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.

Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.

Further detail

=== Sovereignty === Favored distribution of vaccines within one or a few select countries, called "vaccine sovereignty", is a criticism of some of the vaccine development partnerships, such as for the AstraZeneca-University of Oxford vaccine candidate, concerning whether there may be prioritized distribution first within the UK and to the "highest bidder" – the United States, which made an advance payment of US$1.2 billion to secure 300 million vaccine doses for Americans, even before the AstraZeneca-Oxford vaccine or a Sanofi vaccine was proved safe or effective. Concerns exist about whether some countries producing vaccines may impose protectionist controls by export restrictions that would stockpile a COVID‑19 vaccine for their own population. The Chinese government pledged in May 2020, that a successful Chinese vaccine would become a "global, public good", implying enough doses would be manufactured for both national and global distribution. Unlike mRNA vaccines, which have to be stored at subzero temperatures, inactivated vaccines from Sinovac and Sinopharm require ordinary refrigeration and may have more appeal in developing countries. In November 2021, the Chinese government pledged to donate in 2022 a further 600 million vaccine doses to Africa, and supply another 400 million through other routes including production by Chinese companies in Africa.

=== Separation Processes === King wrote the book Separation Processes in 1971. In the book, King presented that each of the separation processes (distillation, extraction, absorption, etc.) is a special case of a unified technology that can be described by a general set of quantitative principles. Before that, the standard separation operations were considered to be separate topics within the category of unit operations, with separate methodologies. The book was revised for a second edition in 1980. After the book went out of print, King secured the copyright back from McGraw-Hill and put it on eScholarship, where it is available open-access.

== References == Butler, Rohan, MA., Bury, J.P.T., MA., & Lambert M.E., MA., editors, Documents on British Foreign Policy 1919–1939, 1st Series, Her Majesty's Stationery Office, London, 1960, vol. x, Chapter VIII, "The Plebiscites in Allenstein and Marienwerder January 21 – September 29, 1920" Keynes, John Maynard. A Revision of the Treaty: Being a Sequel to The Economic Consequences of the Peace, Harcourt, Brace, 1922 Kossert, Andreas. Masuren: Ostpreussens vergessener Süden, ISBN 3-570-55006-0 (in German) Mayer, S. L., MA. History of the First World War – Plebiscites:Self Determination in Action, Peter Young, MA., editor, BPC Publishing Ltd., UK., 1971. Rhode, Gotthold. Die Ostgebiete des Deutschen Reiches, Holzner-Verlag Würzburg, 1956. Tooley, T. Hunt. National Identity and Weimar Germany: Upper Silesia and the Eastern Border, 1918–1922, U of Nebraska Press, 1997, ISBN 0-8032-4429-0 Topolski, Jerzy. An Outline History of Poland, Interpress, 1986, ISBN 83-223-2118-X Wambaugh, Sarah. Plebiscites since the World War, Washington DC, 1933. I pp 99–141; II pp 48–107 Williamson, David G. The British in Germany 1918–1930, Oxford, 1991, ISBN 0-85496-584-X

He played Sigmund Freud's father in Freud: The Secret Passion (1962) with Montgomery Clift in the lead. He was also well known for his story-telling skills, particularly in reinterpreting the Bible. His best-known book, also a television series, is The Book of Witnesses (1971), in which he turned the Gospels into a series of monologues. He also retold dozens of Old Testament and Apocrypha stories in Bible Stories (1968).

== Limitations == Despite its widespread use, the mdx mouse has several important limitations as a model for Duchenne muscular dystrophy. The mdx mouse displays a considerably milder phenotype than human DMD patients, largely due to the compensatory upregulation of utrophin. In 2016, despite decades of successful preclinical studies in mdx mice, many promising therapies failed in human clinical trials, highlighting the translational gap between the mouse model and human disease. To overcome these limitations, researchers have developed improved models such as the mdx/utrophin double knockout mouse, which more closely resembles the severe human DMD phenotype, and humanized mdx models that allow testing of human-specific therapies such as exon skipping drugs.

Sources: en.wikipedia.org

Background from the literature

He lived out the last ten years of his life addicted to chloral and alcohol, in part to mask the pain of botched surgery to an enlarged testicle in 1877. Oliver Sacks (1933–2015) abused chloral hydrate in 1965 as a depressed insomniac. He found himself taking fifteen times the usual dose of chloral hydrate every night before he eventually ran out, causing violent withdrawal symptoms. Anna Nicole Smith (1967–2007) died of "combined drug intoxication" with chloral hydrate as the "major component". John Tyndall (1820–1893), an Irish physicist, died of an accidental overdose of chloral administered by his wife. Evelyn Waugh (1903–1966), insomniac for much of his adult life, for which "in later life ... he became so deleteriously dependent on chloral". Waugh's novel, The Ordeal of Gilbert Pinfold, is largely a fictionalised account of an episode Waugh himself experienced as a result of excessive use of chloral in combination with bromide and alcohol. Waugh's friend and biographer Christopher Sykes observed that Waugh's description of D. G. Rossetti's demise under the effects of excessive use of chloral in his 1928 biography of the artist "is a fairly exact description of how [Waugh's own] life ended in 1966". Country music singer Hank Williams (1923–1953) died from a combination of chloral hydrate, morphine and whiskey. Renée Vivien (1877-1909), a prominent lesbian poet during the Belle Époque, abused chloral hydrate for much of her life.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. The US Food and Drug Administration considers it to be a first-in-class medication.

In May 1952, Raymond Gosling, a graduate student working under the supervision of Rosalind Franklin, took an X-ray diffraction image, labeled as "Photo 51", at high hydration levels of DNA. This photo was given to Watson and Crick by Maurice Wilkins and was critical to their obtaining the correct structure of DNA. Franklin told Crick and Watson that the backbones had to be on the outside. Before then, Linus Pauling, and Watson and Crick, had erroneous models with the chains inside and the bases pointing outwards. Franklin's identification of the space group for DNA crystals proved her correct. In February 1953, Linus Pauling and Robert Corey proposed a model for nucleic acids containing three intertwined chains, with the phosphates near the axis, and the bases on the outside. Watson and Crick completed their model, which is now accepted as the first correct model of the double helix of DNA. On 28 February 1953 Crick interrupted patrons' lunchtime at The Eagle pub in Cambridge, England to announce that he and Watson had "discovered the secret of life".

=== Halides === Actinium trifluoride can be produced either in solution or in solid reaction. The former reaction is carried out at room temperature, by adding hydrofluoric acid to a solution containing actinium ions. In the latter method, actinium metal is treated with hydrogen fluoride vapors at 700 °C (1,292 °F) in an all-platinum setup. Treating actinium trifluoride with ammonium hydroxide at 900–1,000 °C (1,650–1,830 °F) yields oxyfluoride AcOF. Whereas lanthanum oxyfluoride can be easily obtained by burning lanthanum trifluoride in air at 800 °C (1,470 °F) for an hour, similar treatment of actinium trifluoride yields no AcOF and only results in melting of the initial product.

Sources: en.wikipedia.org

Frequently asked questions

In which form is semax typically supplied?

Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.

Does semax occur naturally?

No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.

Why is it grouped with nootropics?

The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.

What receptor system does it engage?

It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.

Network